U.S. Banks Stock News

Skyworks Solutions (SWKS) has been grinding through a tough stretch, with the stock down sharply over the past year even as revenue and net income still managed to grow modestly. See our latest analysis for Skyworks Solutions. That weak year to date share price return of around negative 27 percent and a roughly negative 26 percent total shareholder return over the past year suggest sentiment has cooled, even as modest growth keeps longer term recovery potential on the table. If Skyworks has...

MARA Holdings (MARA) is back in focus after insider stock sales by its CEO and CFO surfaced, alongside a strategic pivot toward energy and compute infrastructure projects developed with MPLX. See our latest analysis for MARA Holdings. The insider sales and strategic shift arrive after a tough stretch for shareholders, with a 30 day share price return of minus 11.33 percent and a one year total shareholder return of minus 50.67 percent, even though the three year total shareholder return of...

Starfighters Space (FJET) has exploded onto investors radar after its NYSE American debut, with a $40 million IPO quickly followed by extreme trading swings and intense debate over how to value this hypersonic launch story. See our latest analysis for Starfighters Space. That frenzy has already fed into performance, with the share price return still up around 45.9% year to date at a latest share price of $12.40. This suggests momentum remains strong despite wild swings around the IPO and...

On 22 December 2025, BillionToOne, Inc. (NasdaqGS:BLLN) was added to the S&P Total Market Index, expanding its presence in broad U.S. equity benchmarks. This index inclusion can be material because it often prompts benchmark-tracking funds and other institutional investors to consider the stock for portfolio inclusion. We’ll now examine how BillionToOne’s entry into the S&P Total Market Index could influence its investment narrative and perceived market standing. Rare earth metals are an...

In December 2025, uniQure reported that final minutes from its pre-Biologics License Application meeting showed the FDA views existing Phase I/II data for AMT-130 as insufficient to support a filing, pushing the company to seek further regulatory discussions in fiscal Q1 2026. This feedback directly affects the timeline and evidence required for AMT-130 in Huntington’s disease, potentially reshaping how investors assess uniQure’s lead gene therapy program within its broader pipeline. We’ll...

Wondering if Intercontinental Exchange is still a smart buy at around $162 a share, or if most of the upside has already been priced in? Let us unpack what the market might be implying about its long term value. The stock has climbed 1.1% over the last week, 6.4% over the past month, and is up 9.3% over the past year, adding to strong 3 year and 5 year gains of 65.3% and 53.2% respectively. Those moves sit against a backdrop of ICE steadily expanding its exchanges and data businesses, while...

PagerDuty (PD) is back in the spotlight after law firm Levi & Korsinsky launched an investigation into potential securities law violations, following the company’s disclosure of weaker customer retention and trimmed full year revenue guidance. See our latest analysis for PagerDuty. The share price has slid to about $13.04 after a 23.7% drop on November 26. That weak reaction lines up with a 1 year total shareholder return of roughly minus 29%, suggesting momentum is clearly fading as...

In the third quarter of 2025, Hong Kong-based Athos Capital acquired 2.5 million KE Holdings shares, a new US$47.5 million stake that became its largest disclosed holding at 29.8% of reportable assets. This sizable commitment by a specialist regional fund highlights investor confidence in KE Holdings’ profitability, expanding rental and existing-home businesses, strong cash position, and more than US$2.30 billion of cumulative share repurchases since 2022 despite a weak housing...

DexCom (DXCM) is in an awkward spotlight right now, with fresh class action lawsuits alleging it overstated the safety and reliability of its G6 and G7 devices, even as it just secured FDA clearance for its Smart Basal technology. See our latest analysis for DexCom. Investors seem torn between DexCom’s legal overhang and its growth story, with an 8.4% 1 month share price return but a 1 year total shareholder return of roughly negative 16%, suggesting fading longer term momentum despite recent...

Dyne Therapeutics (DYN) just added seasoned rare disease executive Vikram Karnani to its board, a move that lines up neatly with the company’s push toward commercialization and helps explain the renewed interest in the stock. See our latest analysis for Dyne Therapeutics. The appointment lands after a choppy stretch, with the share price returning 61.76% over the past 90 days but a 1 year total shareholder return of negative 15.10%. This suggests momentum is rebuilding as execution risk feels...

Harmonic (HLIT) just landed a meaningful showcase customer, as Czech Television moves its video streaming workflow onto Harmonic’s XOS Advanced Media Processor to gain tighter control, higher quality delivery and more inclusive viewing features. See our latest analysis for Harmonic. The deal lands at an interesting time for investors, with Harmonic’s share price at $9.97 and a 1 month share price return of 10.65 percent, contrasting with a weaker year to date share price return and softer 1...

Harley-Davidson recently closed all 629 US dealerships for 24 hours on Christmas Day, and is preparing a January 14, 2026 "Chapter 2" event to unveil its 2026 model lineup with mechanical and aesthetic updates. The upcoming "Chapter 2" reveal positions Harley-Davidson to showcase how refreshed models and design changes might support its longer-term brand and product transition efforts. Now we’ll explore how the planned "Chapter 2" 2026 model reveal could influence Harley-Davidson’s...

In the past quarter, law firms Hagens Berman and Robbins Geller Rudman & Dowd launched investigations into Ardent Health after its Q3 2025 disclosure of a US$97 million adverse accounting adjustment, including a US$54 million claims-related charge and a US$43 million reserve timing change. These probes center on whether Ardent’s leadership knew about weaknesses in revenue recognition and liability reserve controls before disclosing them, raising questions about the reliability of its...

Philip Morris International (NYSE:PM) just put income investors back in the spotlight, reaffirming its quarterly dividend at 1.47 dollars per share ahead of the December 26 ex dividend date and a closely watched FDA review for ZYN. See our latest analysis for Philip Morris International. The reaffirmed dividend, new credit facilities and looming FDA decision on ZYN are all feeding into sentiment, with Philip Morris International’s 34.3% year to date share price return pointing to building...

Mohawk Industries (MHK) just went through a rare index shuffle, getting dropped from the S&P 500 Equal Weighted Index but added to both the S&P 1000 and Russell Small Cap Value Index. See our latest analysis for Mohawk Industries. Those index moves come after a choppy stretch, with the share price at $110.03 and a weak 90 day share price return suggesting momentum has cooled, even though the three year total shareholder return remains solidly positive. If Mohawk’s shifting index profile has...

United States Antimony recently secured a five-year, sole-source contract with the U.S. Defense Logistics Agency worth up to US$245,000,000 for antimony metal ingots, alongside a separate five-year commercial supply agreement for antimony trioxide valued at up to US$106,700,000, and is expanding its Montana smelter capacity sixfold to support these commitments. Together with a new independent director appointment and increased ore preparation ahead of winter, these moves underline United...

Northern Trust Corporation recently announced several leadership changes, effective January 1, 2026, including appointing Clive Bellows and Guy Gibson as co-presidents of Asset Servicing, naming Melanie Pickett as chief transformation officer, and confirming the retirement of long-serving executive Teresa Parker. The creation of a firmwide chief transformation officer role, reporting directly to the CEO, signals a stronger internal push to accelerate innovation and adapt to evolving client...

Earlier this week, Amdocs reported earnings that narrowly beat backlog expectations but missed next-quarter EPS guidance, while unveiling new cloud migration and digital transformation deals with major telecom operators across North America, Europe, Latin America, and Asia. A key takeaway is Amdocs’ ability to win large, long-term modernization and generative AI projects even as near-term profitability guidance softens. We’ll now examine how these new cloud and generative AI transformation...

Upcoming earnings put Dow (DOW) under a cautious spotlight Market attention is turning to Dow (DOW) ahead of its January 29, 2026 earnings release, with Wall Street bracing for a year over year revenue decline and recently trimmed profit expectations. See our latest analysis for Dow. The share price has drifted lower over the year, with a year to date share price return of about negative 42 percent and a roughly negative 38 percent one year total shareholder return. This suggests sentiment...

On December 19, 2025, the FDA approved MYQORZO for obstructive hypertrophic cardiomyopathy, triggering Royalty Pharma’s 4.5% royalty on up to US$5.00 billion in sales and activating additional structured funding rights with Cytokinetics. This approval adds a fresh cardiovascular royalty stream and long-tail, 1.9x-repayment funding exposure, strengthening Royalty Pharma’s visibility on future cash flows. We’ll now examine how this newly activated MYQORZO royalty stream could reshape Royalty...

In December 2025, a group of eighteen student pilots filed a complaint against American Airlines, its Cadet Academy partner Coast Flight Training, and American Airlines Federal Credit Union, alleging false promises about training timelines, costs, and career outcomes, and seeking US$36.00 million in damages. The lawsuit also accuses American Airlines and its partners of systemic racial discrimination and “reverse redlining” in the Cadet Academy, raising fresh questions about the airline’s...

AT&T's board recently declared quarterly dividends on its 5.000% Series A and 4.750% Series C preferred stock, alongside a US$0.2775 common-share dividend, all payable on February 2, 2026 to holders of record as of January 12, 2026. Analyst commentary from Goldman Sachs and Morgan Stanley has drawn attention to AT&T’s expanding fiber network and plans for capital returns, reshaping how investors weigh its income profile against growth ambitions. We’ll now examine how the focus on fiber...

Denali Therapeutics (DNLI) just wrapped up a $200 million secondary offering, strengthening its cash position as it talks with the FDA about a potential priority review voucher that could speed key programs. See our latest analysis for Denali Therapeutics. The fresh capital raise comes after a choppy stretch, with a 90 day share price return of 26.51 percent but a 1 year total shareholder return of negative 18.79 percent, suggesting momentum is rebuilding from a lower base. If this financing...

CorMedix (CRMD) has quietly put together an impressive run, with the stock up about 48% this year and more than tripling over the past 3 years, grabbing investors' attention again. See our latest analysis for CorMedix. That strength has not been a one off move, with a 30 day share price return of about 24% and a three year total shareholder return above 220% pointing to clear positive momentum. If CorMedix is on your radar, this could also be a good moment to explore other healthcare names...